Home > Healthcare > Medical Devices > Diagnostic Devices > Ovarian Cancer Diagnostic Market

Ovarian Cancer Diagnostic Market Trends

Report ID: GMI8316
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Ovarian Cancer Diagnostic Market Trends

Advances in medical imaging, molecular biology, and genetic testing have revolutionized ovarian cancer diagnostics. High-resolution imaging modalities, such as MRI and PET-CT scans, provide detailed visualization of ovarian tumors and metastases, aiding in accurate diagnosis and staging.

Furthermore, the development of molecular, immunological assays, and genetic tests allows for the identification of specific biomarkers associated with ovarian cancer, facilitating personalized treatment strategies and prognostic assessments.
For instance, in November 2022, Roche announced the FDA's approval of the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, marking the first immunohistochemistry (IHC) companion diagnostic test authorized to aid in the identification of epithelial ovarian cancer (EOC) patients.
Moreover, improved awareness campaigns and the implementation of screening programs have contributed to the early detection of ovarian cancer.
Women are becoming more informed about the signs and symptoms of ovarian cancer, leading to earlier consultation with healthcare providers and increased uptake of screening tests.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global ovarian cancer diagnostic industry was valued at around USD 1.54 billion in 2023 and is estimated to reach over USD 2.71 billion by 2032, driven by increasing incidences of ovarian cancer worldwide.

Instruments/analyzers segment garnered USD 965.7 million in 2023 and is set to gain traction by 2032, driven by technological advancements and growing awareness about the importance of early detection and screening for ovarian cancer.

North America ovarian cancer diagnostic industry accounted for USD 624.4 million in 2023 and is predicted to witness substantial growth through 2032, driven by an advanced healthcare infrastructure and high levels of awareness regarding the importance of early cancer detection.

Abbott Laboratories, Agilent Technologies, Canon Medical Systems Corporation, Danaher Corporation, F. Hoffmann-La Roche Ltd., Fujirebio Diagnostics, GE HealthCare Technologies Inc., Illumina Inc., Myriad Genetics, Philips Healthcare, Positron Corporation are some of the major industry contenders.